US stock futures dip as Trump’s firing of Cook sparks Fed independence fears
Ronald Craig Janish, the Executive Vice President of Global Operations and Supply Chain and Chief Technology Officer at Perrigo Co plc (NYSE:PRGO), a $3.7 billion market cap pharmaceutical company, recently reported a series of transactions involving the company’s ordinary shares. On March 10, 2025, Janish sold 7,800 shares at $27.44 each, totaling $214,032. This sale reduced his direct ownership to 33,666 shares. According to InvestingPro data, Perrigo has maintained dividend payments for 23 consecutive years and currently shows strong financial health metrics.
In addition to the sale, Janish was involved in several acquisitions and other transactions. On March 6 and 7, 2025, he acquired a total of 17,355 shares at a price of $27.76, amounting to $481,774. These transactions included the vesting of performance-based restricted stock units granted in March 2022. With analyst price targets ranging from $27 to $42, InvestingPro analysis suggests the stock may be slightly undervalued at current levels.
Further, Janish executed option exercises on March 6 and 7, acquiring 5,241 shares at prices ranging from $27.76 to $28.68, with a total value of $147,606. Additionally, he disposed of shares for tax withholding purposes, totaling $189,488, with prices also ranging from $27.76 to $28.68.
These transactions reflect Janish’s active management of his holdings in Perrigo, a company in the pharmaceutical preparations sector, headquartered in Dublin, Ireland.
In other recent news, Perrigo Company reported fourth-quarter revenue of $1.29 billion, surpassing analyst expectations of $1.2 billion. However, the company’s adjusted earnings per share were $0.93, slightly below the anticipated $0.95. For the full year 2024, Perrigo’s net sales were $4.37 billion, a decrease of 6.1% from the previous year, while adjusted diluted EPS was $2.57, aligning with its guidance range. The company attributed its Q4 success to a 17% increase in infant formula net sales, driven by market share gains and improved customer inventory levels.
Jefferies analyst Keith Devas recently adjusted Perrigo’s stock price target to $31 from $29, maintaining a Hold rating. Devas noted that Perrigo’s guidance for 2025 and its three-year targets indicate a positive trajectory, although execution on several fronts, such as formula changes and brand streamlining, remains crucial. The company plans to unveil its 2025-2027 strategic plan at a virtual Investor Day event on February 28, where it will also provide fiscal 2025 guidance. Perrigo’s efforts to stabilize and streamline its operations seem to be gaining traction, as reflected in the recent developments.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.